Correct (trial design was part of Keytruda’s success over Opdivo), and, if you recall Dr. Bosch’s presentations about half a decade ago, he was very excited that DCVax increased PDL-1 expression which logically makes it a fit to add Keytruda (a PDL1 inhibitor) in a combo because Keytruda would then have a role in blocking the PDL-1 expression the cancer was trying to use against DCVax in response to DCVax-l’s mechanism of action.
In other words, because DCVax is excellent at creating immune response and tumor infiltration/killing, the Cancer expresses PDL1 to suppress DCVax MOA, and thus PDL1 expression is increased which means that by that point, Keytruda could be used to prohibit/downgrade that suppression.
Market Data 
Markets 
AI
